{
    "xml": "<topic id=\"PHP5906\" outputclass=\"drug\" rev=\"1.11\" type=\"drug\" namespace=\"/drugs/methoxy-polyethylene-glycol-epoetin-beta\" basename=\"methoxy-polyethylene-glycol-epoetin-beta\" title=\"METHOXY POLYETHYLENE GLYCOL-EPOETIN BETA\">\n<title>METHOXY POLYETHYLENE GLYCOL-EPOETIN BETA</title>\n<body>\n<data name=\"vtmid\">426360006</data>\n<data name=\"classifications\">\n<data name=\"classification\">\n<data name=\"drugClassification\">\n<xref format=\"dita\" scope=\"local\" type=\"drugClassification\" href=\"#_511920681\" title=\"Continuous erythropoietin receptor activators\">Continuous erythropoietin receptor activators</xref>\n</data>\n</data>\n</data>\n<data name=\"primaryDomainOfEffect\">\n<data name=\"domainOfEffect\">  </data>\n</data>\n</body>\n<topic id=\"PHP46268\" outputclass=\"indicationsAndDose\" rev=\"1.18\" parent=\"/drugs/methoxy-polyethylene-glycol-epoetin-beta\">\n<title>Indications and dose</title>\n<body>\n<section outputclass=\"indicationAndDoseGroup\">\n<sectiondiv outputclass=\"therapeuticIndications\">\n<p outputclass=\"therapeuticIndication\">Symptomatic anaemia associated with chronic kidney disease in patients on dialysis and not currently treated with erythropoietins</p>\n</sectiondiv>\n<p outputclass=\"routesOfAdministration\">By subcutaneous injection or by intravenous injection</p>\n<ul outputclass=\"patientGroups\">\n<li outputclass=\"patientGroup adult\">\n<p>Adult</p>\n<p>Initially 600&#8239;nanograms/kg every 2&#8239;weeks, dose to be adjusted according to response at intervals of at least 4 weeks, maintenance dose of double the previous fortnightly dose may be given every 4 weeks, reduce dose by approximately 25% if rise in haemoglobin concentration exceeds 2&#8239;g/100&#8239;mL over 4 weeks; or if haemoglobin concentration approaches or exceeds 12&#8239;g/100&#8239;mL; if haemoglobin concentration continues to rise, despite dose reduction, suspend treatment until haemoglobin concentration decreases and then restart at a dose approximately 25% lower than the previous dose.</p>\n</li>\n</ul>\n</section>\n<section outputclass=\"indicationAndDoseGroup\">\n<sectiondiv outputclass=\"therapeuticIndications\">\n<p outputclass=\"therapeuticIndication\">Symptomatic anaemia associated with chronic kidney disease in patients not on dialysis and not currently treated with erythropoietins</p>\n</sectiondiv>\n<p outputclass=\"routesOfAdministration\">Initially by subcutaneous injection</p>\n<ul outputclass=\"patientGroups\">\n<li outputclass=\"patientGroup adult\">\n<p>Adult</p>\n<p>Initially 1.2&#8239;micrograms/kg every 4&#8239;weeks, alternatively (by subcutaneous injection or by intravenous injection) initially 600&#8239;nanograms/kg every 2&#8239;weeks, dose to be adjusted according to response at intervals of at least 4 weeks, patients treated once every 2 weeks may be given a maintenance dose of double the previous fortnightly dose every 4 weeks, subcutaneous route preferred in patients not on haemodialysis. Reduce dose by approximately 25% if rise in haemoglobin concentration exceeds 2&#8239;g/100&#8239;mL over 4 weeks; or if haemoglobin concentration approaches or exceeds 12&#8239;g/100&#8239;mL; if haemoglobin concentration continues to rise, despite dose reduction, suspend treatment until haemoglobin concentration decreases and then restart at a dose approximately 25% lower than the previous dose.</p>\n</li>\n</ul>\n</section>\n<section outputclass=\"indicationAndDoseGroup\">\n<sectiondiv outputclass=\"therapeuticIndications\">\n<p outputclass=\"therapeuticIndication\">Symptomatic anaemia associated with chronic kidney disease in patients currently treated with erythropoietins</p>\n</sectiondiv>\n<p outputclass=\"routesOfAdministration\">By subcutaneous injection or by intravenous injection</p>\n<ul outputclass=\"patientGroups\">\n<li outputclass=\"patientGroup adult\">\n<p>Adult</p>\n<p>(consult product literature).</p>\n</li>\n</ul>\n</section>\n</body>\n</topic>\n<topic id=\"PHP46146\" outputclass=\"sideEffects\" rev=\"1.9\" parent=\"/drugs/methoxy-polyethylene-glycol-epoetin-beta\">\n<title>Side-effects</title>\n<body>\n<section outputclass=\"generalSideEffects\">\n<sectiondiv outputclass=\"frequencies\">\n<sectiondiv outputclass=\"notKnown\">\n<p outputclass=\"title\">Frequency not known</p>\n<p outputclass=\"sideEffects\">\n<ph outputclass=\"sideEffect\">Hot flushes</ph>\n</p>\n</sectiondiv>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP46241\" outputclass=\"pregnancy\" parent=\"/drugs/methoxy-polyethylene-glycol-epoetin-beta\">\n<title>Pregnancy</title>\n<body>\n<section outputclass=\"generalInformation\">\n<sectiondiv>\n<p>No evidence of harm in <i>animal</i> studies&#8212; manufacturer advises caution.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP46395\" outputclass=\"breastFeeding\" parent=\"/drugs/methoxy-polyethylene-glycol-epoetin-beta\">\n<title>Breast feeding</title>\n<body>\n<section outputclass=\"generalInformation\">\n<sectiondiv>\n<p>Manufacturer advises use only if potential benefit outweighs risk&#8212;present in milk in <i>animal</i> studies.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP5906-medicinalForms\" outputclass=\"medicinalForms\" parent=\"/drugs/methoxy-polyethylene-glycol-epoetin-beta\">\n<title>Medicinal forms</title>\n<body>\n<section outputclass=\"licensingVariationStatement\">\n<p>There can be variation in the licensing of different medicines containing the same drug.</p>\n</section>\n</body>\n</topic>\n<parents>\n<xref format=\"dita\" scope=\"local\" type=\"drugs\" href=\"#drugs\" title=\"Drugs\" namespace=\"/drugs\">Drugs</xref>\n</parents>\n<children>\n<xref format=\"dita\" scope=\"local\" type=\"medicinalForm\" href=\"#PHP74715\" title=\"Solution for injection\" namespace=\"/drugs/methoxy-polyethylene-glycol-epoetin-beta/solution-for-injection\">Solution for injection</xref>\n</children>\n<backlinks>\n<xref format=\"dita\" scope=\"local\" type=\"drugClassifications\" href=\"#PHP106980\" namespace=\"/drug-classifications\" title=\"Drug classifications\" count=\"1\" rel=\"backlink\">Drug classifications</xref>\n<xref format=\"dita\" scope=\"local\" type=\"treatmentSummary\" href=\"#PHP78590\" namespace=\"/treatment-summaries/anaemias\" title=\"Anaemias\" count=\"1\" rel=\"backlink\">Anaemias</xref>\n</backlinks>\n<links>\n<xref format=\"dita\" scope=\"local\" type=\"#drugs\" href=\"#drugs\" namespace=\"/drugs\" title=\"Drugs\" count=\"1\" rel=\"link\">Drugs</xref>\n<xref format=\"dita\" scope=\"local\" type=\"medicinalForm\" href=\"#PHP74715\" namespace=\"/drugs/methoxy-polyethylene-glycol-epoetin-beta/solution-for-injection\" title=\"Solution for injection\" count=\"1\" rel=\"link\">Solution for injection</xref>\n</links>\n</topic>",
    "id": "PHP5906",
    "outputclass": "drug",
    "rev": "1.11",
    "type": "drug",
    "namespace": "/drugs/methoxy-polyethylene-glycol-epoetin-beta",
    "basename": "methoxy-polyethylene-glycol-epoetin-beta",
    "title": "METHOXY POLYETHYLENE GLYCOL-EPOETIN BETA",
    "vtmid": "426360006",
    "drugClassification": [
        "Continuous erythropoietin receptor activators"
    ],
    "primaryDomainOfEffect": {
        "": {
            "domain": "",
            "therapeuticUses": {}
        }
    },
    "indicationsAndDoses": {
        "indicationAndDoseGroups": [
            {
                "indications": [
                    {
                        "textContent": "Symptomatic anaemia associated with chronic kidney disease in patients on dialysis and not currently treated with erythropoietins",
                        "html": "Symptomatic anaemia associated with chronic kidney disease in patients on dialysis and not currently treated with erythropoietins"
                    }
                ],
                "specificity": {
                    "routes": [
                        "subcutaneous injection or intravenous injection"
                    ],
                    "textContent": "By subcutaneous injection or by intravenous injection",
                    "html": "By subcutaneous injection or by intravenous injection"
                },
                "adult": [
                    {
                        "textContent": "Initially 600 nanograms/kg every 2 weeks, dose to be adjusted according to response at intervals of at least 4 weeks, maintenance dose of double the previous fortnightly dose may be given every 4 weeks, reduce dose by approximately 25% if rise in haemoglobin concentration exceeds 2 g/100 mL over 4 weeks; or if haemoglobin concentration approaches or exceeds 12 g/100 mL; if haemoglobin concentration continues to rise, despite dose reduction, suspend treatment until haemoglobin concentration decreases and then restart at a dose approximately 25% lower than the previous dose.",
                        "html": "<p>Initially 600&#8239;nanograms/kg every 2&#8239;weeks, dose to be adjusted according to response at intervals of at least 4 weeks, maintenance dose of double the previous fortnightly dose may be given every 4 weeks, reduce dose by approximately 25% if rise in haemoglobin concentration exceeds 2&#8239;g/100&#8239;mL over 4 weeks; or if haemoglobin concentration approaches or exceeds 12&#8239;g/100&#8239;mL; if haemoglobin concentration continues to rise, despite dose reduction, suspend treatment until haemoglobin concentration decreases and then restart at a dose approximately 25% lower than the previous dose.</p>"
                    }
                ]
            },
            {
                "indications": [
                    {
                        "textContent": "Symptomatic anaemia associated with chronic kidney disease in patients not on dialysis and not currently treated with erythropoietins",
                        "html": "Symptomatic anaemia associated with chronic kidney disease in patients not on dialysis and not currently treated with erythropoietins"
                    }
                ],
                "specificity": {
                    "routes": [
                        "Initially subcutaneous injection"
                    ],
                    "textContent": "Initially by subcutaneous injection",
                    "html": "Initially by subcutaneous injection"
                },
                "adult": [
                    {
                        "textContent": "Initially 1.2 micrograms/kg every 4 weeks, alternatively (by subcutaneous injection or by intravenous injection) initially 600 nanograms/kg every 2 weeks, dose to be adjusted according to response at intervals of at least 4 weeks, patients treated once every 2 weeks may be given a maintenance dose of double the previous fortnightly dose every 4 weeks, subcutaneous route preferred in patients not on haemodialysis. Reduce dose by approximately 25% if rise in haemoglobin concentration exceeds 2 g/100 mL over 4 weeks; or if haemoglobin concentration approaches or exceeds 12 g/100 mL; if haemoglobin concentration continues to rise, despite dose reduction, suspend treatment until haemoglobin concentration decreases and then restart at a dose approximately 25% lower than the previous dose.",
                        "html": "<p>Initially 1.2&#8239;micrograms/kg every 4&#8239;weeks, alternatively (by subcutaneous injection or by intravenous injection) initially 600&#8239;nanograms/kg every 2&#8239;weeks, dose to be adjusted according to response at intervals of at least 4 weeks, patients treated once every 2 weeks may be given a maintenance dose of double the previous fortnightly dose every 4 weeks, subcutaneous route preferred in patients not on haemodialysis. Reduce dose by approximately 25% if rise in haemoglobin concentration exceeds 2&#8239;g/100&#8239;mL over 4 weeks; or if haemoglobin concentration approaches or exceeds 12&#8239;g/100&#8239;mL; if haemoglobin concentration continues to rise, despite dose reduction, suspend treatment until haemoglobin concentration decreases and then restart at a dose approximately 25% lower than the previous dose.</p>"
                    }
                ]
            },
            {
                "indications": [
                    {
                        "textContent": "Symptomatic anaemia associated with chronic kidney disease in patients currently treated with erythropoietins",
                        "html": "Symptomatic anaemia associated with chronic kidney disease in patients currently treated with erythropoietins"
                    }
                ],
                "specificity": {
                    "routes": [
                        "subcutaneous injection or intravenous injection"
                    ],
                    "textContent": "By subcutaneous injection or by intravenous injection",
                    "html": "By subcutaneous injection or by intravenous injection"
                },
                "adult": [
                    {
                        "textContent": "(consult product literature).",
                        "html": "<p>(consult product literature).</p>"
                    }
                ]
            }
        ]
    },
    "sideEffects": {
        "general": {
            "frequencies": {
                "notKnown": [
                    {
                        "type": "notKnown",
                        "textContent": "Hot flushes",
                        "html": "Hot flushes",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "Frequency not known",
                            "html": "Frequency not known"
                        }
                    }
                ]
            }
        }
    },
    "pregnancy": {
        "generalInformation": [
            {
                "type": "generalInformation",
                "textContent": "No evidence of harm in animal studies&#8212; manufacturer advises caution.",
                "html": "<p>No evidence of harm in <i>animal</i> studies&#8212; manufacturer advises caution.</p>"
            }
        ]
    },
    "breastFeeding": {
        "generalInformation": [
            {
                "type": "generalInformation",
                "textContent": "Manufacturer advises use only if potential benefit outweighs risk&#8212;present in milk in animal studies.",
                "html": "<p>Manufacturer advises use only if potential benefit outweighs risk&#8212;present in milk in <i>animal</i> studies.</p>"
            }
        ]
    },
    "medicinalForms": {
        "licensingVariationStatement": [
            {
                "type": "licensingVariationStatement",
                "textContent": "There can be variation in the licensing of different medicines containing the same drug.",
                "html": "<p>There can be variation in the licensing of different medicines containing the same drug.</p>"
            }
        ]
    },
    "children": {
        "medicinalForm": [
            {
                "id": "PHP74715",
                "label": "Solution for injection",
                "type": "medicinalForm"
            }
        ]
    },
    "backlinks": {
        "drugClassifications": [
            {
                "id": "PHP106980",
                "label": "Drug classifications",
                "type": "drugClassifications"
            }
        ],
        "treatmentSummary": [
            {
                "id": "PHP78590",
                "label": "Anaemias",
                "type": "treatmentSummary"
            }
        ]
    },
    "links": {
        "#drugs": [
            {
                "id": "drugs",
                "label": "Drugs",
                "type": "#drugs"
            }
        ],
        "medicinalForm": [
            {
                "id": "PHP74715",
                "label": "Solution for injection",
                "type": "medicinalForm"
            }
        ]
    }
}